Sanofi expanded collaboration with Dren Bio for discovery and development of next-generation B-cell depletion therapy. $100M upfront and up to $1.7B in development/regulatory/commercial milestones. Dren has option for 40% co-funding/50% US profit share arrangement. Builds on March 2025 DR-0201 acquisition.